Key facts
- Many Americans have not seen relief from rising drug and insurance costs.
- Pfizer committed to offering all its prescription medications to Medicaid at 'most favored nation' prices.
- Medicaid net spending on prescription drugs grew 46% between 2019 and 2024.
- The pilot program relies on voluntary participation from drug companies and states.
President Trump has promoted his administration's efforts to lower prescription drug prices, citing deals with pharmaceutical companies as a key accomplishment. However, a year after announcing agreements, many Americans have not experienced a reduction in their drug costs or insurance premiums. A voluntary agreement with Pfizer, announced on September 30, 2025, aimed to reduce prices for some medications, particularly for those covered by Medicaid. The initiative, dubbed TrumpRx, was intended to bring U.S. prices in line with those in other wealthy nations. Despite promises that 26 companies signed similar deals, the agreements have not been publicly released, and details about which drugs will be discounted remain unclear. Companies like Gilead, Sanofi, and Eli Lilly have confirmed they will offer discounts on selected products, but not necessarily all of their medications. The program's reliance on voluntary participation from both drug companies and states has led to uncertainties and delays, hindering its widespread implementation.